T cell depletion of the graft increases graft failure and relapse rate in allogeneic PBSC transplantation. Delayed lymphocyte add-back after T cell-depleted transplants might prevent these complications. We The success of allogeneic progenitor stem cell transplantation is mainly limited by the morbidity and mortality caused by GVHD and tumor relapse. Donor T-lymphocytes play a critical role in the pathogenesis of GVHD, which may therefore be prevented by T cell depletion of the graft. However, T-lymphocytes facilitate donor engraftment and contribute to the eradication of various hematologic malignancies. T cell depletion of the graft has been associated with a higher incidence of graft-failure and leukemia relapse.
The success of allogeneic progenitor stem cell transplantation is mainly limited by the morbidity and mortality caused by GVHD and tumor relapse. Donor T-lymphocytes play a critical role in the pathogenesis of GVHD, which may therefore be prevented by T cell depletion of the graft. However, T-lymphocytes facilitate donor engraftment and contribute to the eradication of various hematologic malignancies. T cell depletion of the graft has been associated with a higher incidence of graft-failure and leukemia relapse. [1] [2] [3] Many strategies have been tested in order to prevent GVHD without compromising the GVL effect: partial T cell depletion of a specific subset of lymphocytes; 4 maintenance of a minimal threshold of lymphocytes in the depleted graft; 5 or recently, the administration of delayed DLI. [6] [7] [8] [9] DLI reverts disease relapse after allogeneic transplantation, which indicates that delayed donor lymphocytes retain their antitumor effect. [10] [11] [12] [13] Moreover, in a murine model the timing of DLI appears to influence the induction of GVHD. 14 Mobilized PBSC from the donor have been used for allogeneic transplantation, 15 but this approach is associated with a higher incidence of chronic GVHD. 16, 17 Allogeneic transplantation of CD34 + -selected cells has been used to decrease GVHD incidence. 18, 19 Prophylactic or pre-emptive DLI after hematopoietic stem cell transplant may prevent relapse. This approach has been used in small groups of patients receiving allogeneic bone marrow transplantation with promising results. 6, 7, 9 However, there are few data on this approach after CD34-selected allogeneic PBSC transplantation. 8, 20 As GVHD induced by T cells from the donor is associated with a GVL effect, we aimed to conserve the antileukemic effect, while preventing and controlling GVHD through the delayed administration of increasing doses of T-lymphocytes.
We designed a protocol in which prophylactic DLI was adjusted for each patient depending on their risk of relapsing or developing GVHD, in order to derive the maximal benefit from the GVL effect without provoking an uncontrolled GVHD.
Patients and methods

Patients and donors
Between September 1997 and December 2000, 22 consecutive adult patients with hematologic malignancies received a hematopoietic progenitor transplant from an HLA-identical sibling. Recipient age ranged between 17 and 57 years (mean, 41). The diagnoses were: CML (10 patients: nine in chronic phase and one in accelerated phase), AML (seven patients), ALL (three patients), MDS (one patient), CLL (one patient) and Hodgkin's disease (one patient).
Patients were transplanted a mean of 6 months after diagnosis (range 3-72).
Written informed consent was obtained from all patients and donors. Clinical characteristics of patients and donors are listed in Table 1 .
Cytogenetic study revealed abnormalities in three patients with AML (t(12;17) trisomy 8 and complex karyotype) and in two patients with ALL (t(9;22)).
Stem cell collection and processing
Peripheral blood progenitor cells were mobilized from the donor with G-CSF 8 g/kg twice daily s.c. (Lenogastrin; Chugai-Rhône-Poulenc, Antony, France) for 5 or 6 consecutive days. Collection was performed in one (10 donors) 21 Cells were directly infused without cryopreservation.
Preparative regimens and supportive care
Seventeen patients received a preparative regimen consisting of cyclophosphamide 60 mg/kg once daily i.v. on days −5 and −6, and TBI 325 cGy once daily on days −4 to −1 at a rate of 8-12 cGy/min. Four patients also received etoposide 60 mg/kg i.v. on day −7 because they had uncontrolled active disease. One patient with history of prior radiotherapy received busulfan 16 mg/kg orally instead of TBI.
T cell add-back
Patients were considered for different schedules of prophylactic DLI depending on the risk of relapse and the risk of developing GVHD. We considered standard risk of relapse when AML was observed in first CR, ALL in first or second CR, CML in first chronic phase, NHL in first CR, MDS and Hodgkin's disease in first CR. Any other situation was considered as a high risk of relapse. Patients were considered at high risk of developing GVHD if older than 35 years or if the donor was sensitized through previous pregnancies or blood transfusion.
The schedule for DLI was: 2 ϫ 10 5 CD3 + /kg on days +28 and +60, and 2 ϫ 10 6 CD3 + /kg on day +90 after transplantation. T cells were directly obtained from the donor without previous G-CSF administration and through direct peripheral blood extraction.
Patients at high risk of developing GVHD were scheduled to receive two DLI if they had a high risk of relapse, or none if they had standard risk of relapse. Patients at low risk of developing GVHD were scheduled to receive three DLI if they had high risk of relapse, or two DLI if at standard risk of relapse (Table 2) .
If the patient developed acute GVHD уII, the DLI program was withdrawn. 
Post-transplant management
Post-transplant growth factor was not administered in any case. GVHD prophylaxis consisted of cyclosporin 3 mg/kg daily i.v. starting on day −1 followed by oral cyclosporine when tolerated. Cyclosporine dose was adjusted to maintain a cyclosporine plasma level between 200 and 400 g/ml and then tapered at day +120 post transplantation if no GVHD had appeared. CMV antigen was monitored weekly until day +120 post transplantation and patients were started on gancyclovir when the antigenemia was positive. Acute GVHD ϾII was treated with methylprednisolone 2 mg/kg daily for 3 days and then tapered according to response. Extensive chronic GVHD was treated with prednisolone 0.5-1 mg/kg and cyclosporine on alternate days.
Chimerism studies
Chimerism studies were performed on peripheral blood samples, analyzing the whole blood, as well as the fractions obtained after Ficoll-Hypaque gradient density separation (granulocytes and mononuclear cells). The engraftment was quantified by amplification of a panel of VNTRs and STRs with fluorescent-labelled primers. The amplified fluorescent PCR products were separated on an automated DNA sequencer (ALFexpressII) (Amersham Pharmacia, Uppsala, Sweden).
Statistical analysis
Chi-square test was used to compare categorical values. Actuarial probabilities of survival, relapse and GVHD were calculated by the method of Kaplan-Meier. 22 
Results
Engraftment characteristics
In one (10 patients) or two (12 patients) leukapheresis procedures, a mean of 8.9 ϫ 10 6 CD34 + cells/kg (range 3.1-14.7) were obtained from the donor. After the positive selection, a mean number of 4.4 × 10 6 CD34 + cells/kg (range 1.9-10.6) and 0.085 ϫ 10 4 CD3 + cells/kg (range 0.01-0.67) were infused to the patients. The mean number of CD3 + cells/kg infused was always below 1 ϫ 10
5
, which is assumed to be the threshold for the development of GVHD. 23 Recovery was satisfactory in all the patients and no graft failed. The mean numbers of days to reach neutrophil counts of 0.5 ϫ 10 presented overt fungal infection, and only five patients were started on amphotericin B due to persistent fever and neutropenia. Six patients presented with CMV reactivation and were satisfactorily treated with gancyclovir or foscarnet, only one patient with severe acute GVHD developed overt CMV disease involving the lung and died. Overall survival was 65% CI (43-86%) with a mean follow-up of 585 days (range 89-1103) (Figure 1 ) and the expected mean survival for the whole group is 775 Ϯ 196 days. The event-free survival was 33% (11-55%). The actuarial risk of relapse was 54% CI (29-79%) ( Figure 2 ). However, many relapsing patients were rescued through therapeutic DLI and the final survival in CR was 56% CI (33-80%) (Figure 1 ).
There were no differences in overall survival depending on the risk of relapse and of developing GVHD. There was a tendency to higher survival for patients with a diagnosis of CML (79% CI (52-100%)).
No early transplant-related mortality was observed. At the time of writing, 14 patients are alive in CR, one patient Bone Marrow Transplantation is alive in relapse (undergoing therapeutic DLI), four patients have died of relapse (three belonged to the high risk and one to the standard risk group) and three have died of chronic GVHD. Ten patients have relapsed (four CML, four acute leukemia and one chronic lymphocytic leukemia), five patients out of 12 (42%) belonging to the standard risk of relapse and five patients out of 10 (50%) belonging to the highrisk group.
All the patients relapsing from CML achieved CR after therapeutic DLI. However, one patient died of severe GVHD when in CR. The patient with CLL and one patient with AML achieved CR after therapeutic DLI. One patient is still receiving therapeutic DLI, which failed in the remaining three patients with acute leukemia.
T cell add-back
Twenty-two DLI were performed in 12 patients as scheduled in the protocol (five AML, two CML, two ALL, one RAEB, one CLL, one Hodgkin's disease). Ten patients belonged to the category of standard risk of relapse and high risk of developing GVHD and were not planned to receive the T cell add-back.
Eight patients were scheduled to receive two DLI. Five of them developed acute GVHD following the first infusion, so they were not given the second. Four patients were at low risk of developing GVHD and had advanced disease: three of them completed three prophylactic lymphocyte infusion and the fourth presented GVHD after the second DLI. No patient presented with pancytopenia after T cell infusion.
GVHD
The risk of developing acute GVHD ϾII was 28% CI (7-49%) and extensive chronic GVHD was 38% CI (10-63%) ( Figure 3 ). Thirteen patients from the whole group developed acute GVHD (six grade I, three grade II, one grade III) and five patients developed chronic GVHD (one limited and four extensive). There was no difference in the incidence of extensive chronic GVHD between patients that received DLI and patients that did not (Figure 4 ). Seven out of 12 patients presented GVHD after prophylactic DLI (three grade I aGVHD, two grade II aGVHD, one grade III aGVHD, three patients showed extensive chronic GVHD). Three patients died with chronic GVHD, two of them with lung involvement. One of these patients did not received any prophylactic DLI, and the other two received only one or two low-dose DLI (2 ϫ 10 5 CD3/kg). Five relapsing patients developed cGVHD (three extensive) after therapeutic DLI.
Chimerism determination
Chimerism status was examined immediately after transplant and monthly thereafter. All the patients presented complete donor chimerism or more than 90% of donor hematopoiesis.
Discussion
In the present study, we attempted to decrease relapse rate after allogeneic transplant with T cell-depleted graft through delayed add-back of T cells from the donor. Moreover, the use of prophylactic DLI has also been proposed to guarantee engraftment and to facilitate immunological reconstitution.
A high dose of CD34 + cells has been associated with prevention of relapse in BM and PBSC transplants, even in T cell-depleted grafts. 6, 24, 25 Mobilized PBSC were used to obtain higher doses of CD34 + cells than those obtained from bone marrow. In our study, the patients received a mean of 4.4 ϫ 10 6 CD34 + /kg, which is greater than the minimal dose recommended by Bahçeci et al. 6 The DLI add-back schedule was adjusted for patients according to their risk of relapse or developing GVHD. The risk of developing GVHD after DLI correlates positively with the dose of T cells infused 26, 27 and with the time elapsed between transplant and infusion. 28 Some studies reported an incidence of acute GVHD grade II or more after therapeutic DLI of 5% with doses of 2 ϫ 10 6 CD3 + /kg and 0% with 2 ϫ 10 5 CD3 + /kg. Although Mackinnon et al 26 did not observe a GVL effect at the lower dose, they used DLI to treat relapse rather than prevent it. We therefore considered that prophylactic DLI with T cell doses of 2 ϫ 10 5 CD3 + /kg on days +28 and +60, and 2 ϫ 10 6 CD3 + /kg on day +90 after transplantation, while patients were on cyclosporin A, would not significantly increase the risk of GVHD.
Engraftment was rapid and sustained in all our patients, in spite of their receiving grafts with a mean T cell dose of 0.18 ϫ 10 5 CD3 + /kg. Only one patient presented secondary graft failure in the presence of severe aGVHD and CMV disease under gancyclovir treatment. Although we believe that the high number of CD34 + cells facilitated the engraftment, T cell add-back at low doses may have prevented graft rejection which has been reported 2 to have an incidence of 18.5% in patients receiving T cell doses of less than 0.07 × l0 6 CD3/kg. Previous studies in T celldepleted bone marrow had suggested that additional T cells in the range of 1-10 ϫ 10 5 /kg might prevent rejection. 5, 9 T cell-depleted transplantation is an expensive procedure compared to non-T cell-depleted transplant but is associated with a lower morbidity (lower incidence of acute and chronic GVHD). The low transplant-related mortality reported here may be attributed to the delay in the onset of GVHD, to the low incidence of severe aGVHD or to the number of CD34 + cells infused. 6, 9 We applied the T cell add-back protocol in an attempt to reduce the relapse rate. The overall risk of relapse was 54%. Patients at standard risk of relapse showed a higher incidence of relapse than that reported for patients receiving non-T cell-depleted inoculum. 3 However, relapsing patients in our study easily re-entered CR with therapeutic DLI without developing uncontrolled GVHD, especially for patients with the diagnosis of CML. The diagnosis of CML was the only factor associated with improved survival.
Our preliminary data show that DLI protected a subgroup of patients at a high risk of relapse. We found a similar DFS for patients with advanced acute leukemia and patients in first CR. Although this is not statistically significant, likely due to the limited number of patients in each group, the DFS in the high-risk group was better than expected.
As expected, the incidence of acute GVHD ϾII (28%) and extensive chronic GVHD (32%) is slightly higher in our study than that described after allogeneic transplant with CD34
+ selection of the mobilized PBSC by UrbanoIspizua et al 18 from the Spanish group experience (10% for acute GVHD ϾII and 12% for extensive chronic GVHD). A study of pre-emptive CD8-depleted DLI after CD34-selected PBSC transplant 29 showed a much lower incidence of aGVHD and cGVHD than in a historical cohort of non-T cell-depleted BMT. In contrast, some groups 7,9 report an overall incidence of GVHD equivalent to that of the non-T cell-depleted BMT, so they conclude that T cell add-back administered in the early phase of transplant invariably induces GVHD. In our study GVHD was controlled by
Bone Marrow Transplantation withholding doses of immunocompetent lymphocytes in patients at high risk of GVHD or when a clinically relevant GVHD appeared. Moreover, GVHD was easily controlled with conventional therapy. The high incidence of GVHD found by other groups after prophylactic DLI may also be due to a higher dose of DLI or the lack of cyclosporine protection. 8, 20, 30 Previous attempts to separate the GVL effect from GVHD have failed. 7, 9 However, specific lymphocyte subsets (CD8 + ) are being tested with promising results. 29 Our study does not show significantly that the GVL effect can be achieved without GVHD because the number of patients is too low. Only nine out of 16 patients without GVHD (acute уII or extensive chronic GVHD) relapsed. In contrast, only one out of six patients with GVHD relapsed (P = 0.27). Lee et al 9 in a group of 144 allogeneic T celldepleted bone marrow transplants with DLI (90 related, 54 unrelated) could not separate GVL from GVHD, and GVHD seemed necessary to prevent relapse.
We conclude that acute leukemia patients who do not develop GVHD may benefit from more DLI (larger T cell doses and for longer) to improve survival in both standard and high risk of relapse. We now intend to improve the DLI by optimizing the schedule in patients who show a progressive decrease of donor chimerism. Another approach could be the administration of more selective immunotherapy through a selected lymphocyte population or vaccines. 31 In our study there was no increase in the incidence of infectious episodes in spite of high T cell depletion. The low incidence of uncontrolled GVHD and the high dose of CD34 cells administered may have protected our patients from CMV disease in spite of a high incidence of CMV positivity in the donor and the recipient.
In contrast to other reports, 8 the compliance was excellent and most of the patients received planned T cell addback. All of them received the first DLI due to the absence of GVHD. This may be related to the low dose of lymphocytes and the early administration after transplant while patients were receiving cyclosporin.
Our report presents one of the largest and most homogeneous cohorts of patients receiving prophylactic DLI after PBSC transplants. Patients were stratified by their risk of relapse and of developing GVHD. Our strategy differs from previous published studies because the schedule and total dose of lymphocyte administered was adjusted individually for each patient. Prophylactic DLI at the doses we used with an escalating schedule was not associated with an increase in GVHD incidence.
Further studies are needed to define the optimal schedule of cell-mediated immunotherapy for effective prevention of relapse following T cell-depleted transplantation in malignant hematological disorders.
